568.9500 -7.20 (-1.25%)
NSE Sep 07, 2026 12:30 PM
Volume: 118.7K
 

568.95
-1.25%
ICICI Securities Limited
Thyrocare Technologies’ (Thyrocare) Q1FY27 performance was ahead of our expectations. Outperformance was led by strong traction in both pathology segments, with franchises growing at ~27% YoY and partnerships at ~26%.
Number of FII/FPI investors increased from 137 to 144 in Jun 2026 qtr.
More from Thyrocare Technologies Ltd.
Recommended